Federated Hermes’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,291,172
| Closed | -$2.08M | – | 2057 |
|
|
2025
Q4 | $2.08M | Buy |
1,291,172
+651,800
| +102% | +$1.36M | ﹤0.01% | 952 |
|
|
2025
Q3 | $1.75M | Buy |
639,372
+22,054
| +4% | +$73.4K | ﹤0.01% | 974 |
|
|
2025
Q2 | $2.25M | Sell |
617,318
-296,131
| -32% | -$814K | ﹤0.01% | 912 |
|
|
2025
Q1 | $1.75M | Sell |
913,449
-554
| -0.1% | -$1.13K | ﹤0.01% | 968 |
|
|
2024
Q4 | $1.74M | Buy |
914,003
+45,982
| +5% | +$79.8K | ﹤0.01% | 966 |
|
|
2024
Q3 | $1.15M | Buy |
868,021
+2,769
| +0.3% | +$3.7K | ﹤0.01% | 1075 |
|
|
2024
Q2 | $883K | Sell |
865,252
-1,302
| -0.2% | -$1.61K | ﹤0.01% | 1150 |
|
|
2024
Q1 | $1.59M | Hold |
866,554
| – | – | ﹤0.01% | 999 |
|
|
2023
Q4 | $1.07M | Sell |
866,554
-98,639
| -10% | -$101K | ﹤0.01% | 1112 |
|
|
2023
Q3 | $1.1M | Hold |
965,193
| – | – | ﹤0.01% | 1083 |
|
|
2023
Q2 | $883K | Sell |
965,193
-54,839
| -5% | -$52.9K | ﹤0.01% | 1179 |
|
|
2023
Q1 | $571K | Hold |
1,020,032
| – | – | ﹤0.01% | 1366 |
|
|
2022
Q4 | $589K | Sell |
1,020,032
-780,504
| -43% | -$245K | ﹤0.01% | 1317 |
|
|
2022
Q3 | $569K | Sell |
1,800,536
-188,931
| -9% | -$74.1K | ﹤0.01% | 1304 |
|
|
2022
Q2 | $702K | Sell |
1,989,467
-40,548
| -2% | -$17K | ﹤0.01% | 1268 |
|
|
2022
Q1 | $1.46M | Sell |
2,030,015
-4,332
| -0.2% | -$9.27K | ﹤0.01% | 1116 |
|
|
2021
Q4 | $4.6M | Buy |
2,034,347
+5,244
| +0.3% | +$14.3K | 0.01% | 835 |
|
|
2021
Q3 | $5.84M | Buy |
2,029,103
+145,327
| +8% | +$415K | 0.01% | 789 |
|
|
2021
Q2 | $7.14M | Buy |
1,883,776
+1,882,252
| +123,507% | +$6.34M | 0.01% | 748 |
|
|
2021
Q1 | $5K | Hold |
1,524
| – | – | ﹤0.01% | 2057 |
|
|
2020
Q4 | $4K | Sell |
1,524
-309,797
| -100% | -$905K | ﹤0.01% | 2065 |
|
|
2020
Q3 | $781K | Buy |
311,321
+38,362
| +14% | +$337K | ﹤0.01% | 1342 |
|
|
2020
Q2 | $3.71M | Buy |
+272,959
| New | +$2.82M | 0.01% | 796 |
|
|
2019
Q4 | – | Sell |
-6,789
| Closed | -$27K | – | 2205 |
|
|
2019
Q3 | $27K | Buy |
6,789
+519
| +8% | +$2.22K | ﹤0.01% | 1795 |
|
|
2019
Q2 | $30K | Sell |
6,270
-1,234
| -16% | -$7.02K | ﹤0.01% | 1745 |
|
|
2019
Q1 | $61K | Sell |
7,504
-682
| -8% | -$4.68K | ﹤0.01% | 1636 |
|
|
2018
Q4 | $45K | Sell |
8,186
-1,868
| -19% | -$14.6K | ﹤0.01% | 1670 |
|
|
2018
Q3 | $89K | Buy |
10,054
+9,731
| +3,013% | +$87K | ﹤0.01% | 1681 |
|
|
2018
Q2 | $3K | Buy |
323
+42
| +15% | +$420 | ﹤0.01% | 2063 |
|
|
2018
Q1 | $3K | Buy |
281
+15
| +6% | +$210 | ﹤0.01% | 2017 |
|
|
2017
Q4 | $4K | Sell |
266
-251
| -49% | -$4.16K | ﹤0.01% | 2008 |
|
|
2017
Q3 | $10K | Buy |
517
+273
| +112% | +$4.2K | ﹤0.01% | 1839 |
|
|
2017
Q2 | $4K | Buy |
+244
| New | +$3.09K | ﹤0.01% | 1976 |
|
Other funds holding AKBA
VCM
VPM
Federated Hermes's AKBA Position: Q1 2026 in Review
Federated Hermes sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 1,291,172 shares — an estimated $2.08M sold.
Federated Hermes first reported a position in AKBA in Q2 2017 and held it in 33 quarters. The position peaked at $7.14M in Q2 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Federated Hermes reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
- Federated Hermes sold 1,291,172 Akebia Therapeutics shares in Q1 2026, an estimated $2.08M.
- Federated Hermes first reported a position in Akebia Therapeutics in Q2 2017 and held it in 33 quarters.
- Federated Hermes's Akebia Therapeutics position peaked at $7.14M in Q2 2021.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.